Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 1

Xehetasun bibliografikoak
Parent link:Physiology and Pharmacology
Vol. 21, iss. 1.— 2017.— [P. 25-33]
Erakunde egilea: Национальный исследовательский Томский политехнический университет (ТПУ) Институт неразрушающего контроля (ИНК) Кафедра экологии и безопасности жизнедеятельности (ЭБЖ)
Beste egile batzuk: Fedorenko O. Yu. Olga Yurievna, Loonen A. J. M. Anton, Vyalova N. M. Nataljya Mikhaylovna, Boyko A. S. Anastasiya Sergeevna, Pozhidaev I. V. Ivan, Osmanova D. Z. Diana, Rakhmazova L. D. Lyubov Demjyanovna, Bokhan N. A. Nikolay Aleksandrovich, Ivanov M. V. Mikhail Valerjevich, Freydin M. V., Ivanova S. A. Svetlana Aleksandrovna
Gaia:Title screen
Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia.
Hizkuntza:ingelesa
Argitaratua: 2017
Gaiak:
Sarrera elektronikoa:http://phypha.ir/ppj/browse.php?a_id=1205&
Formatua: Baliabide elektronikoa Liburu kapitulua
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=656082

MARC

LEADER 00000naa0a2200000 4500
001 656082
005 20250402092527.0
035 |a (RuTPU)RU\TPU\network\22473 
035 |a RU\TPU\network\12550 
090 |a 656082 
100 |a 20171023d2017 k||y0rusy50 ba 
101 0 |a eng 
102 |a IR 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia  |f O. Yu. Fedorenko [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: p. 32-33 (21 tit.)] 
330 |a Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia. 
337 |a Adobe Reader 
461 |t Physiology and Pharmacology 
463 |t Vol. 21, iss. 1  |v [P. 25-33]  |d 2017 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a шизофрения 
610 1 |a гиперпролактинемия 
610 1 |a антипсихотические препараты 
610 1 |a полиморфизм 
610 1 |a гены 
610 1 |a schizophrenia 
610 1 |a hyperprolactinemia 
610 1 |a antipsychotics 
610 1 |a gene polymorphism 
701 1 |a Fedorenko  |b O. Yu.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1973-  |g Olga Yurievna  |3 (RuTPU)RU\TPU\pers\33861  |9 17450 
701 1 |a Loonen  |b A. J. M.  |g Anton 
701 1 |a Vyalova  |b N. M.  |g Nataljya Mikhaylovna 
701 1 |a Boyko  |b A. S.  |g Anastasiya Sergeevna 
701 1 |a Pozhidaev  |b I. V.  |g Ivan 
701 1 |a Osmanova  |b D. Z.  |g Diana 
701 1 |a Rakhmazova  |b L. D.  |g Lyubov Demjyanovna 
701 1 |a Bokhan  |b N. A.  |g Nikolay Aleksandrovich 
701 1 |a Ivanov  |b M. V.  |g Mikhail Valerjevich 
701 1 |a Freydin  |b M. V. 
701 1 |a Ivanova  |b S. A.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1964-  |g Svetlana Aleksandrovna  |3 (RuTPU)RU\TPU\pers\33859 
712 0 2 |a Национальный исследовательский Томский политехнический университет (ТПУ)  |b Институт неразрушающего контроля (ИНК)  |b Кафедра экологии и безопасности жизнедеятельности (ЭБЖ)  |3 (RuTPU)RU\TPU\col\18720 
801 2 |a RU  |b 63413507  |c 20171023  |g RCR 
856 4 |u http://phypha.ir/ppj/browse.php?a_id=1205& 
942 |c CF